Shangya Technology Co (6130) Fair Value & Analysis
Healthcare · TW · Market cap 1.2B TWD
Fair value as of: Jun 25, 2026
Analysis
Shangya Technology Co (6130) currently trades at 22.95 TWD, while our model-based Fair Value estimate is 7.73 TWD — implying the stock looks roughly 66.3% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Shangya Technology Co., Ltd. engages in the generic drugs and solar power generation businesses in Taiwan and Asia. The company wholesales Chinese and Western medicines, medical equipment, and beauty and hair care products; and onrito, lixin fumitation, lufuxing film-coated, amperex film coating, leverb-coated, triton film-coated, special core stabilized, tanlipo film-coated, inhibitory film-coated, yoyo flat mouth dissolved, and binlishu film-coated tablet, as well as pain relief capsules and yue shi tong injection. It is also involved in the research, development, production, and sale of wireless communication integrated circuits, satellite positioning system integrated circuits, and portable product ICs. The company was formerly known as Singbao International Co. Ltd and changed its name to Shangya Technology Co., Ltd. in July 2023. Shangya Technology Co., Ltd. was founded in 1994 and is based in Taipei, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Shangya Technology Co (6130) undervalued?
What is the fair value of 6130?
What is the quality score of 6130?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.